Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Advertisement
Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC

Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.

Research & Development Clinical Trials

Momentum For ViroMed's Gene Therapy After ‘Exceptional’ Trial Go-Ahead In China

China FDA has granted earlier-than-expected approval to begin a Phase III clinical trial of ViroMed's gene therapy VM202. Successful trials in China are expected to support global commercialization of the first-in-class therapy for cardiovascular and neurological diseases, which is also in late-stage clinical development in the US.

Research & Development Clinical Trials

Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea

Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.

Commercial Biosimilars

What Korean Pharma Wants To Build On Innovation Momentum

A recent policy forum in Seoul discussed why the South Korean government and the pharma industry should work in tandem to take forward thriving innovation in the country and how faster approval timelines can aid this process.

Policy & Regulation Clinical Trials

Korea’s Biotech Roadmap Aims To Bridge Funding Gaps

South Korea reaffirms its supportive policy stance for the biotech industry with a new long-term roadmap. The plan covers the entire cycle of drug development, including R&D support to tackle the industry’s ‘valley of death’ and creation of a mega fund to help companies enter global markets.

Research & Development South Korea

Medifron Move Signals Alzheimer’s R&D Acceleration In Korea

Medifron DBT's plan to make a sizable investment in its Alzheimer’s disease drug pipelines may be followed by further South Korean biotechs and pharmas accelerating development in the field as the country steps up support for dementia R&D.

South Korea Financing
See All
Advertisement
UsernamePublicRestriction

Register